Precirix
Biotechnology company developing precision radiopharmaceuticals in oncology
Precirix has raised €80M across 1 funding round from 9 investors, most recently a Series B round in Mar 2022. Based in Brussels, Belgium; active in Healthtech. Data as of 28 Oct 2026.
Brussels, Belgiumwww.precirix.com ↗
Total raised
€80M
€80,000,000
Funding rounds
1
Investors
9
distinct backers
Active since
2022-03
latest 2022-03
Funding by year
EUR raised per yearPrecirix — funding by year — interactive chart.
Data table
| Precirix — funding by year | |
|---|---|
| 2022 | €80M |
Signals
High confidenceRaise-next likelihood9
base rate 48% for Series B
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-03-16 | Series B | €80M | BioMedPartners,Forbion,GIMV,HealthCap,INKEF Capital,Jeito Capital+3 more | View deal → |
Investors
9Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Imec€2.5BBelgium · Deeptech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Kpler€1.0BBelgium · Software
Global coverage: FundingData